Who are Vectren's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): (+)-Ketoprofen, MOFEZOLAC, Profenol, Rengasil, Ro 205720, Zomiperac.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isoxicam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vectren — Competitive Intelligence Brief

Vectren (ISOXICAM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: isoxicam. Area: Pain.

marketed isoxicam Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 Pain Small molecule Live · refreshed every 30 min

Target snapshot

Vectren (ISOXICAM).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vectren TARGET	ISOXICAM		marketed	isoxicam	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01
MOFEZOLAC	MOFEZOLAC		marketed	mofezolac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1	1994-01-01
Profenol	SUPROFEN	Novartis	marketed	suprofen	Cytochrome P450 2C9, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1988-01-01
Rengasil	PIRPROFEN		marketed	pirprofen	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1987-01-01
Ro 205720	CARPROFEN	Roche	marketed	carprofen	Complement C5, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1987-01-01
Zomiperac	ZOMEPIRAC		marketed	zomepirac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase	1980-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (isoxicam class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vectren — Competitive Intelligence Brief. https://druglandscape.com/ci/isoxicam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab